Recent breakthroughs in optical scattering-based imaging have enabledvisualization of entities as small as single proteins. Leveraging our innovation, Surface Enhanced Scattering Microscopy (SESM), detection of single protein binding kinetics and single DNA conformational changes have been achieved, showcasing the feasibility of single molecule imaging. In this dissertation, I aim to harness the potential of SESM and extend its relevance in the biomedical realm. My first goal is to conduct multiplexed protein detection and parallel binding kinetics analysis with label-free digital single- molecule counting. My second goal is focused on accurate quantification of cell force. An elastic model has been developed to quantify the cell-substrate interactions and have continuously tracked cell force evolutions upon small-molecule drugs (for example, acetylcholine) stimulation, achieving a temporal resolution of approximately 60 ms over the course of 30 min without attenuating the signals. The third goal is to achieve real- time tracking of DNA self-assembly dynamics. I have demonstrated SESM's capability to image individual DNA origami monomers and established an on-chip temperature annealing system to monitor the real-time progression of DNA self-assembly. The applications of the imaging method, spanning single proteins, single DNA origami, and single cells, are poised to impact the field of biology

Cardiovascular diseases are the number one cause of death worldwide. Cardiac biomarkers can provide objective and quantitative information to facilitate early diagnosis and guide treatment of cardiovascular diseases. Even though a variety of methods have been developed for cardiac biomarker detection, a point-of-care testing (POCT) for cardiac biomarkers with high sensitivity, specificity and precision is still missing. To fulfil this unmet need, novel digital biosensing methods based on optical imaging and nanomaterials are developed in this dissertation for high-sensitivity POCT of cardiac biomarkers.First, a high-sensitivity and POC-compatible optical imaging-based digital immunoassay is developed for rapid detection of low-abundance biomarkers. This technology was established on a model analyte IL-6 and can be adapted to various other protein targets. The digital immunoassay was also utilized as the reference method for evaluating the digital nanobiosensors developed afterwards. Second, a microfluidic digital nanobiosensor (MDNB) is developed for POC-compatible detection of heart failure biomarker NT-proBNP from 7 µL of whole blood. Using the MDNB, detection in a clinically relevant concentration range was achieved with a 10-minute assay time. With a high potential utility in outpatient and possibly even home settings, the MDNB could become a POC device for decentralized detection of NT-proBNP to assist heart failure patient management. Lastly, the development of a digital immunogold-linked apta-sorbent assay (DILASA) for rapid high-sensitivity detection of heart attack biomarker cardiac troponin is introduced. Reliable detection of 10 ng/L cTnT in human plasma was achieved with a 15-minute assay time using DILASA. It is expected that with further optimization and development, DILASA will be a promising candidate approach for realizing a high-sensitivity POCT of cTnT.

Detection technologies and physical methods used for separation of complex molecules can be effective tools in research when applied to bioparticles including, but not limited to, bacteria, viruses, and proteins. Dielectrophoresis (DEP) is a technique that has been used in microfluidics for separation and concentration of bioparticles, with the benefits of not requiring custom primers, utilizing small sample sizes, and relatively quick separation times for rapid identification of pathogens such as viruses. As demonstrated in this study, a DEP device using polydimethylsiloxane (PDMS) as an insulator was used for the identification and separation of a mouse hepatitis coronavirus (MHV), a model coronavirus that only infects mice. Results indicate that, using 10 microliters of MHV test sample diluted in buffer, the virus can be identified and separated within 30 seconds using DC voltage of 800 V.

Obesity has consistently presented a significant challenge, with excess body fat contributing to the development of numerous severe conditions such as diabetes, cardiovascular disease, cancer, and various musculoskeletal disorders. In this study, different methods are proposed to study substrate utilization (carbohydrates, proteins, and fats) in the human body and validate the biomarkers enabling to investigation of weight management and monitor metabolic health. The first technique to study was Indirect calorimetry, which assessed Resting Energy Expenditure (REE) and measured parameters like oxygen consumption (VO2) and carbon dioxide production (VCO2). A validation study was conducted to study the effectiveness of the medical device Breezing Med determining REE, VO2, and VCO2. The results were compared with correlation slopes and regression coefficients close to 1. Indirect Calorimetry can be used to determine carbohydrate and fat utilization but it requires additional correction for protein utilization. Protein utilization can be studied by analyzing urinary nitrogen. Therefore, a secondary technique was studied for identifying urea and ammonia concentration in human urine samples. Along this line two methods for detecting urea were explored, a colorimetric technique and it was validated against the Ion-Selective method. The results were then compared by correlation analysis of urine samples measured with both methods simultaneously curves. The equations for fat, carb, and protein oxidation, involving VO2, VCO2 consumption, and urinary nitrogen were implemented and validated, using the above-described methods in a human subject study with 16 subjects. The measurements included diverse diets (normal vs. high fat/protein) in normal energy balance and pre-/post interventions of exercise, fasting, and a high-fat meal. It can be concluded that the indirect calorimetry portable method in conjunction with urine urea methods are important to help the understanding of substrate utilization in human subjects, and therefore, excellent tools to contribute to the treatments and interventions of obesity and overweighted populations.

Evolving knowledge about the tumor microenvironment (TME) is driving innovation in designing novel therapies against hard-to-treat breast cancer. Addressing the immune elements within the tumor microenvironment (TME) has emerged as a highly encouraging strategy for treating cancer. Although current immunotherapies have made advancements in reinstating the body's ability to fight tumors, the search for effective cancer treatments to combat tumor evasion remains a formidable challenge. In line with this objective, there is a pressing need to better understand the complex tumor-immune dynamics and crosstalk within the TME. To evaluate the cancer-immune interaction, this study aimed at investigating the crosstalk between naïve macrophages and cytotoxic T cells in driving tumor progression using an organotypic 3D ex vivo tumor on-a-chip model. The presented microfluidic platform consists of two distinct regions namely: The tumor region and the stroma region separated by trapezoidal microposts to ensure interconnectivity between regions thereby incorporating high spatial organization. In the established triculture platform, the complex Tumor Immune Microenvironment was successfully recapitulated by incorporating naïve macrophage and T cells within an appropriate 3D matrix. Through invasion and morphometric analyses, definitive outcomes were obtained that underscore the significant contribution of macrophages in facilitating tumor progression. Furthermore, the inclusion of T cells led to a notable decrease in the migratory speed of cancer cells and macrophages, underscoring the reciprocal communication between these two immune cell populations in the regulation of tumor advancement. Overall, this study highlights the complexity of TME and underscores the critical role of immune cells in regulating cancer progression.

Chimeric antigen receptor (CAR)-T cell therapy is a type of cancer immunotherapy has shown promising results in engineering the T cells which targets a specific antigen. Despite their success rate, there are certain limitations to the use of CAR-T therapies that includes cytokine release syndrome (CRS), neurologic toxicity, lack of response in approximately 50% of treated patients, monitoring of patients treated with CAR-T therapy. However, rapid point- of- care testing helps in quantifying the circulating CAR T cells and can enhance the safety of patients, minimize the cost of CAR-T cell therapy, and ease the management process. Currently, the standard method to quantify CAR-T cell in patient blood samples are flow cytometry and quantitative polymerase chain reaction (qPCR). But these techniques are expensive and are not easily accessible and suitable for point- of- care testing to assist real- time clinical decisions. To overcome these hurdles, here I propose a solution to these problems by rapid optical imaging (ROI)- based principle to monitor and detect CAR-T cells. In this project, a microfluidic device is developed and integrated with two functions: (1) Centrifuge free, filter- based separation of white blood cells and plasma; (2) Optical imaging- based technique for digital counting of CAR T- cells. Here, I carried out proof- of- concept test on the laser cut prototype microfluidic chips as well as the surface chemistry for specific capture of CAR-T cells. These data show that the microfluidic chip can specifically capture CAR-T positive cells with concentration dependent counts of captured cells. Further development of the technology could lead to a new tool to monitor the CAR-T cells and help the clinicians to effectively measure the efficacy of CAR-T therapy treatment in a faster and safer manner.

Non-invasive biosensors enable rapid, real-time measurement and quantification of biological processes, such as metabolic state. Currently, the most accurate metabolic sensors are invasive, and significant cost is required, with few exceptions, to achieve similar accuracy using non-invasive methods. This research, conducted within the Biodesign Institute Center for Bioelectronics and Biosensors, leverages the selective reactivity of a chemical sensing solution to develop a sensor which measures acetone in the breath for ketosis and ketoacidosis diagnostics, which is relevant to body weight management and type I diabetes. The sensor displays a gradient of color changes, and the absorbance change is proportional to the acetone concentration in the part- per-million range, making applicable for detection ketosis and ketoacidosis in human breath samples. The colorimetric sensor response can be fitted to a Langmuir-like model for sensor calibration. The sensors best performance comes with turbulent, continuous exposure to the samples, rather than batch sample exposure. With that configuration, these novel sensors offer significant improvements to clinical and at- home measurement of ketosis and ketoacidosis.

The development of biosensing platforms not only has an immediate lifesaving effect but also has a significant socio-economic impact. In this dissertation, three very important biomarkers with immense importance were chosen for further investigation, reducing the technological gap and improving their sensing platform.Firstly, gold nanoparticles (AuNP) aggregation and sedimentation-based assays were developed for the sensitive, specific, and rapid detection of Ebola virus secreted glycoprotein (sGP)and severe acute respiratory syndrome coronavirus 2 (SARS-COV2) receptor-binding domain (RBD) antigens. An extensive study was done to develop a complete assay workflow from critical nanobody generation to optimization of AuNP size for rapid detection. A rapid portable electronic reader costing (<$5, <100 cm3), and digital data output was developed. Together with the developed workflow, this portable electronic reader showed a high sensitivity (limit of detection of ~10 pg/mL, or 0.13 pM for sGP and ~40 pg/mL, or ~1.3 pM for RBD in diluted human serum), a high specificity, a large dynamic range (~7 logs), and accelerated readout within minutes. Secondly, A general framework was established for small molecule detection using plasmonic metal nanoparticles through wide-ranging investigation and optimization of assay parameters with demonstrated detection of Cannabidiol (CBD). An unfiltered assay suitable for personalized dosage monitoring was developed and demonstrated. A portable electronic reader demonstrated optoelectronic detection of CBD with a limit of detection (LOD) of <100 pM in urine and saliva, a large dynamic range (5 logs), and a high specificity that differentiates closely related Tetrahydrocannabinol (THC). Finally, with careful biomolecular design and expansion of the portable reader to a dual-wavelength detector the classification of antibodies based on their affinity to SARS-COV2 RBD and their ability to neutralize the RBD from binding to the human Angiotensin-Converting Enzyme 2 (ACE2) was demonstrated with the capability to detect antibody concentration as low as 1 pM and observed neutralization starting as low as 10 pM with different viral load and variant. This portable, low-cost, and versatile readout system holds great promise for rapid, digital, and portable data collection in the field of biosensing.